Patrick Daly

Patrick Daly is an Assistant Editor at AMC Media Group.

Articles by Patrick Daly

Saad Z. Usmani, MD, MBA, FACPThe HemOnc Pulse | November 20, 2024
Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference.
Patrick DalyAcute Myeloid Leukemia | November 12, 2024
Pivekimab sunirine showed single-agent activity across multiple doses in the treatment of patients with AML.
Patrick DalyMeeting News | November 4, 2024
Isolating CD34-positive samples from patients with MDS was better able to detect molecular relapse.
Sangeetha Venugopal, MDThe HemOnc Pulse | November 1, 2024
Dr. Venugopal, of the Sylvester Comprehensive Cancer Center, shares MDS updates from the SOHO 2024 meeting.
Patrick DalyMyeloma | October 31, 2024
This real-world study characterized step-up dosing models for talquetamab in patients with multiple myeloma.
Patrick DalyMyeloma | October 31, 2024
Talquetamab and pomalidomide induced rapid and deep responses in patients with relapsed or refractory multiple myeloma.
Patrick DalyMyeloma | October 31, 2024
The iMMagine-3 randomized trial has begun enrollment of patients with relapsed or refractory multiple myeloma.
Patrick DalyMyeloma | October 31, 2024
OS, infections, hospitalization, and availability off the shelf were preferred treatment attributes of T-cell engagers.
Jamile Shammo, MDMyelodysplastic Syndromes | October 29, 2024
The expert panel discussion led by Jamile Shammo, MD, also noted differences in cell line suppression by mutational profile.
David Swoboda, MDMyelodysplastic Syndromes | October 21, 2024
Dr. David Swoboda discusses the importance of MDS World Awareness Day and what makes MDS unique compared to other diseases.
Adriana Rossi, MDMyeloma | October 16, 2024
Drs. Rossi and Khouri discuss two presentations on the effects of selinexor exposure on CAR-T outcomes in multiple myeloma.
Naval Daver, MDThe HemOnc Pulse | October 22, 2024
Dr. Daver highlights AML news from the Twelfth Annual Meeting of the Society of Hematologic Oncology.
Melissa BadamoTransplantation & Cellular Therapy | October 4, 2024
Bilal Abid, MD, describes how to approach sequencing pirtobrutinib after CAR-T therapy.
Stefano Luminari, MDAggressive B-Cell Lymphoma | October 3, 2024
The positive safety profile of this bispecific antibody makes it well-suited for combination with other treatments.
Adam Kittai, MDChronic Lymphocytic Leukemia | October 8, 2024
Adam Kittai, MD, discusses sequencing pirtobrutinib and CAR-T in the management of CLL with Richter transformation.
Adam Kittai, MDChronic Lymphocytic Leukemia | October 9, 2024
Adam Kittai, MD, of the Icahn School of Medicine, describes three trials on novel therapies for Richter transformation.
Melissa BadamoTransplantation & Cellular Therapy | October 24, 2024
Dr. Abid describes when he uses bispecifics versus CAR-T in his practice at the University of Texas Health Science Center.
Mazyar Shadman, MD, MPHThe HemOnc Pulse | September 27, 2024
Dr. Shadman, of the Fred Hutchinson Cancer Center, shares CLL news from the SOHO 2024 Annual Meeting.
Patrick DalyMyelodysplastic Syndromes | September 26, 2024
COVID-19 infection was strongly correlated with severity, blast cell percentage, and degree of dysplasia in MDS.
Patrick DalyMyelodysplastic Syndromes | September 26, 2024
IDH1 inhibitor therapy significantly improved survival after HMA failure in patients with higher-risk MDS.